Topic: hepatitis B

A U.S. biotech that bought nearly 30 generic drugs from Sandoz in January says it has plans to build its first manufacturing facility in China.

Here is some other vaccine news of note for the week.

The loan and the $192 million cash left at the end of 2017 will support a Heplisav-B sales team and the clinical trials of SD-101.

The £20 million series A backed by GV will help Vaccitech develop an MVA-vectored universal flu vaccine currently in phase 2.

VBI Vaccines is aiming for 2019 approval filings for its hepatitis B vaccine if a head-to-head trial against GSK's entrenched Engerix-B succeeds.

Merck and GSK are coping with hepatitis A vaccine shortages as the U.S. is experiencing deadly outbreaks.

Dynavax is assuming the daunting task of challenging a Big Pharma with a small internal team.

Here's other vaccine news of note for this week.

GSK is taking heat over shortages of its hep B vaccine that led to rationing in the U.K. but didn’t affect its supplies to the U.S. market.

A global shortage of hepatitis B vaccine has developed as both Merck & Co. and GlaxoSmithKline deal with manufacturing issues.